Figure 5.

Wharton’s jelly mesenchymal stem/stromal cell (WJMSC) exosome (-exo) treatment modulates hyperoxic lung transcriptome and blunts hyperoxia (HYRX)-induced inflammation. (A) Poly-A capture RNA-seq of mouse lung tissue at Postnatal Day (PN) 7 was performed on a subset of normoxic (NRMX)-control animals (n = 3), HYRX-control animals (n = 2), and WJMSC-exo–treated mice (n = 3). The heatmap shows the top 50 differentially expressed genes (red [−1] to green [+1] through black) ranked by adjusted P value at PN7. (B) Validation of select whole-lung RNA-seq data and suppression of candidate proinflammatory markers by MSC-exo treatment was assessed by RT-quantitative PCR in separate experiments. Here, our exosome treatments (WJMSC-exos and bone marrow MSC-exos) were plotted together and referred to as MSC-exo. Data are shown as median (minimum–maximum); n = 4–8 per group. *P < 0.05.